303 related articles for article (PubMed ID: 23215686)
1. Co-nanoencapsulated doxorubicin and Dz13 control osteosarcoma progression in a murine model.
Tan ML; Friedhuber AM; Dass CR
J Pharm Pharmacol; 2013 Jan; 65(1):35-43. PubMed ID: 23215686
[TBL] [Abstract][Full Text] [Related]
2. A chitosan-dipotassium orthophosphate hydrogel for the delivery of Doxorubicin in the treatment of osteosarcoma.
Ta HT; Dass CR; Larson I; Choong PF; Dunstan DE
Biomaterials; 2009 Jul; 30(21):3605-13. PubMed ID: 19345993
[TBL] [Abstract][Full Text] [Related]
3. The performance of doxorubicin encapsulated in chitosan-dextran sulphate microparticles in an osteosarcoma model.
Tan ML; Friedhuber AM; Dunstan DE; Choong PF; Dass CR
Biomaterials; 2010 Jan; 31(3):541-51. PubMed ID: 19836833
[TBL] [Abstract][Full Text] [Related]
4. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
Han L; Huang R; Liu S; Huang S; Jiang C
Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
[TBL] [Abstract][Full Text] [Related]
5. Oral administration of edelfosine encapsulated lipid nanoparticles causes regression of lung metastases in pre-clinical models of osteosarcoma.
González-Fernández Y; Brown HK; Patiño-García A; Heymann D; Blanco-Prieto MJ
Cancer Lett; 2018 Aug; 430():193-200. PubMed ID: 29802930
[TBL] [Abstract][Full Text] [Related]
6. The effective combination therapy against human osteosarcoma: doxorubicin plus curcumin co-encapsulated lipid-coated polymeric nanoparticulate drug delivery system.
Wang L; Wang W; Rui Z; Zhou D
Drug Deliv; 2016 Nov; 23(9):3200-3208. PubMed ID: 26987435
[TBL] [Abstract][Full Text] [Related]
7. A nanoparticulate system that enhances the efficacy of the tumoricide Dz13 when administered proximal to the lesion site.
Tan ML; Dunstan DE; Friedhuber AM; Choong PF; Dass CR
J Control Release; 2010 Jun; 144(2):196-202. PubMed ID: 20079783
[TBL] [Abstract][Full Text] [Related]
8. Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery.
Zhang C; Zhao L; Dong Y; Zhang X; Lin J; Chen Z
Eur J Pharm Biopharm; 2010 Sep; 76(1):10-6. PubMed ID: 20472060
[TBL] [Abstract][Full Text] [Related]
9. Charge-conversional PEG-polypeptide polyionic complex nanoparticles from simple blending of a pair of oppositely charged block copolymers as an intelligent vehicle for efficient antitumor drug delivery.
Lv S; Song W; Tang Z; Li M; Yu H; Hong H; Chen X
Mol Pharm; 2014 May; 11(5):1562-74. PubMed ID: 24606535
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
11. Macrophage migration inhibitory factor promotes osteosarcoma growth and lung metastasis through activating the RAS/MAPK pathway.
Wang C; Zhou X; Li W; Li M; Tu T; Ba X; Wu Y; Huang Z; Fan G; Zhou G; Wu S; Zhao J; Zhang J; Chen J
Cancer Lett; 2017 Sep; 403():271-279. PubMed ID: 28642171
[TBL] [Abstract][Full Text] [Related]
12. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles.
Wang H; Zhao Y; Wu Y; Hu YL; Nan K; Nie G; Chen H
Biomaterials; 2011 Nov; 32(32):8281-90. PubMed ID: 21807411
[TBL] [Abstract][Full Text] [Related]
13. Polymeric nanoparticles of cholesterol-modified glycol chitosan for doxorubicin delivery: preparation and in-vitro and in-vivo characterization.
Yu JM; Li YJ; Qiu LY; Jin Y
J Pharm Pharmacol; 2009 Jun; 61(6):713-9. PubMed ID: 19505361
[TBL] [Abstract][Full Text] [Related]
14. Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles.
Lee AL; Dhillon SH; Wang Y; Pervaiz S; Fan W; Yang YY
Mol Biosyst; 2011 May; 7(5):1512-22. PubMed ID: 21350763
[TBL] [Abstract][Full Text] [Related]
15. Chitosan oligosaccharide-arachidic acid-based nanoparticles for anti-cancer drug delivery.
Termsarasab U; Cho HJ; Kim DH; Chong S; Chung SJ; Shim CK; Moon HT; Kim DD
Int J Pharm; 2013 Jan; 441(1-2):373-80. PubMed ID: 23174411
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and antitumor activity of doxorubicin conjugated stearic acid-g-chitosan oligosaccharide polymeric micelles.
Hu FQ; Liu LN; Du YZ; Yuan H
Biomaterials; 2009 Dec; 30(36):6955-63. PubMed ID: 19782395
[TBL] [Abstract][Full Text] [Related]
17. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice.
Koshkina NV; Kleinerman ES; Waidrep C; Jia SF; Worth LL; Gilbert BE; Knight V
Clin Cancer Res; 2000 Jul; 6(7):2876-80. PubMed ID: 10914737
[TBL] [Abstract][Full Text] [Related]
18. Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy.
Li Y; Hou H; Zhang P; Zhang Z
Drug Deliv; 2020 Dec; 27(1):1044-1053. PubMed ID: 32633576
[TBL] [Abstract][Full Text] [Related]
19. Poly(ethyleneglycol)-b-poly(ε-caprolactone-co-γ-hydroxyl-ε- caprolactone) bearing pendant hydroxyl groups as nanocarriers for doxorubicin delivery.
Chang L; Deng L; Wang W; Lv Z; Hu F; Dong A; Zhang J
Biomacromolecules; 2012 Oct; 13(10):3301-10. PubMed ID: 22931197
[TBL] [Abstract][Full Text] [Related]
20. Low-density lipoprotein-coupled N-succinyl chitosan nanoparticles co-delivering siRNA and doxorubicin for hepatocyte-targeted therapy.
Zhu QL; Zhou Y; Guan M; Zhou XF; Yang SD; Liu Y; Chen WL; Zhang CG; Yuan ZQ; Liu C; Zhu AJ; Zhang XN
Biomaterials; 2014 Jul; 35(22):5965-76. PubMed ID: 24768047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
